clinical trial · NCT07753603
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Sling Therapeutics, Inc.·phase3·recruiting·n = 130
Thyroid Eye Disease, TEDGraves OrbitopathylinsitinibPlacebo
brief summary
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
started
Aug 4, 2026
primary completion
Jun 30, 2028
completion
Jun 28, 2030
last updated
Aug 11, 2026
official title
A Phase 3, Randomized, Double-mask, Placebo-controlled Study With Open-label Extension to Evaluate the Efficacy and Safety of Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol